1
|
2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features.
|
Arthritis Care Res (Hoboken)
|
2011
|
3.66
|
2
|
Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis.
|
Arthritis Rheum
|
2008
|
2.56
|
3
|
The diagnostic significance of soluble CD163 and soluble interleukin-2 receptor alpha-chain in macrophage activation syndrome and untreated new-onset systemic juvenile idiopathic arthritis.
|
Arthritis Rheum
|
2007
|
2.56
|
4
|
Consensus treatment plans for new-onset systemic juvenile idiopathic arthritis.
|
Arthritis Care Res (Hoboken)
|
2012
|
2.21
|
5
|
Gene expression profiling of peripheral blood from patients with untreated new-onset systemic juvenile idiopathic arthritis reveals molecular heterogeneity that may predict macrophage activation syndrome.
|
Arthritis Rheum
|
2007
|
2.00
|
6
|
Development of consensus treatment plans for juvenile localized scleroderma: a roadmap toward comparative effectiveness studies in juvenile localized scleroderma.
|
Arthritis Care Res (Hoboken)
|
2012
|
1.84
|
7
|
Measuring process of arthritis care: a proposed set of quality measures for the process of care in juvenile idiopathic arthritis.
|
Arthritis Care Res (Hoboken)
|
2011
|
1.79
|
8
|
Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series.
|
Arthritis Rheum
|
2011
|
1.79
|
9
|
Subtype-specific peripheral blood gene expression profiles in recent-onset juvenile idiopathic arthritis.
|
Arthritis Rheum
|
2009
|
1.56
|
10
|
Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis.
|
Arthritis Rheum
|
2011
|
1.51
|
11
|
Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: interim results from an ongoing multicenter, open-label, extended-treatment trial.
|
Arthritis Rheum
|
2003
|
1.42
|
12
|
Prevalence of and annual ambulatory health care visits for pediatric arthritis and other rheumatologic conditions in the United States in 2001-2004.
|
Arthritis Rheum
|
2007
|
1.42
|
13
|
An i2b2-based, generalizable, open source, self-scaling chronic disease registry.
|
J Am Med Inform Assoc
|
2012
|
1.39
|
14
|
Premature atherosclerosis in pediatric systemic lupus erythematosus: risk factors for increased carotid intima-media thickness in the atherosclerosis prevention in pediatric lupus erythematosus cohort.
|
Arthritis Rheum
|
2009
|
1.37
|
15
|
2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications.
|
Arthritis Rheum
|
2013
|
1.28
|
16
|
Consensus treatments for moderate juvenile dermatomyositis: beyond the first two months. Results of the second Childhood Arthritis and Rheumatology Research Alliance consensus conference.
|
Arthritis Care Res (Hoboken)
|
2012
|
1.25
|
17
|
Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis.
|
Arthritis Rheum
|
2006
|
1.16
|
18
|
Gene expression signatures in polyarticular juvenile idiopathic arthritis demonstrate disease heterogeneity and offer a molecular classification of disease subsets.
|
Arthritis Rheum
|
2009
|
1.15
|
19
|
Juvenile idiopathic arthritis.
|
Pediatr Clin North Am
|
2005
|
1.09
|
20
|
Juvenile idiopathic arthritis.
|
Rheum Dis Clin North Am
|
2007
|
0.97
|
21
|
Comparison of the intraarticular effectiveness of triamcinolone hexacetonide and triamcinolone acetonide in treatment of juvenile rheumatoid arthritis.
|
J Rheumatol
|
2004
|
0.89
|
22
|
Detection of active disease in juvenile idiopathic arthritis: sensitivity and specificity of the physical examination vs ultrasound.
|
J Rheumatol
|
2011
|
0.88
|
23
|
Performance of current guidelines for diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis.
|
Arthritis Rheumatol
|
2014
|
0.87
|
24
|
2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications.
|
Arthritis Care Res (Hoboken)
|
2013
|
0.86
|
25
|
Secondary analysis of APPLE study suggests atorvastatin may reduce atherosclerosis progression in pubertal lupus patients with higher C reactive protein.
|
Ann Rheum Dis
|
2013
|
0.86
|
26
|
Effects of long-term etanercept treatment on growth in children with selected categories of juvenile idiopathic arthritis.
|
Arthritis Rheum
|
2010
|
0.85
|
27
|
Panniculitis, infection, and dermatomyositis: case and literature review.
|
Clin Rheumatol
|
2009
|
0.84
|
28
|
Using registries to identify adverse events in rheumatic diseases.
|
Pediatrics
|
2013
|
0.83
|
29
|
Response of systemic onset juvenile rheumatoid arthritis to etanercept: is the glass half full or half empty?
|
J Rheumatol
|
2005
|
0.81
|
30
|
Systemic lupus erythematosus in children and adolescents.
|
Pediatr Rev
|
2006
|
0.80
|
31
|
Giant coronary artery aneurysms in juvenile polyarteritis nodosa: a case report.
|
Pediatr Rheumatol Online J
|
2012
|
0.79
|
32
|
Prevalence of annexin A5 resistance in children and adolescents with rheumatic diseases.
|
J Rheumatol
|
2011
|
0.78
|
33
|
Novel method to collect medication adverse events in juvenile arthritis: results from the childhood arthritis and rheumatology research alliance enhanced drug safety surveillance project.
|
Arthritis Care Res (Hoboken)
|
2015
|
0.77
|
34
|
Juvenile idiopathic arthritis: an update on current pharmacotherapy and future perspectives.
|
Expert Opin Pharmacother
|
2013
|
0.77
|
35
|
Cranial nerve involvement with juvenile polyarteritis nodosa: clinical manifestations and treatment.
|
Pediatrics
|
2010
|
0.76
|
36
|
Pediatric rheumatic disease: Vaccination in pediatric rheumatic disease--risks and benefits.
|
Nat Rev Rheumatol
|
2012
|
0.76
|
37
|
A dose schedule for intraarticular steroids in juvenile arthritis.
|
J Rheumatol
|
2011
|
0.75
|
38
|
Ultrasound and cartilage thickness in juvenile idiopathic arthritis: new findings, new questions.
|
J Rheumatol
|
2013
|
0.75
|
39
|
Chronic leg ulceration as the presenting feature of diffuse systemic sclerosis in childhood.
|
J Pediatr
|
2011
|
0.75
|
40
|
Panniculitis and lipodystrophy.
|
Curr Opin Rheumatol
|
2002
|
0.75
|
41
|
Flares in pediatric systemic lupus erythematosus.
|
J Rheumatol
|
2007
|
0.75
|
42
|
Systemic juvenile idiopathic arthritis: a review.
|
Pediatr Ann
|
2012
|
0.75
|
43
|
Novel treatment options for juvenile idiopathic arthritis.
|
Expert Rev Clin Pharmacol
|
2015
|
0.75
|
44
|
Treatment of rheumatic diseases in children: special considerations.
|
Rheum Dis Clin North Am
|
2002
|
0.75
|
45
|
Wasabi nose: an underreported complication of cyclophosphamide infusions.
|
Clin Rheumatol
|
2011
|
0.75
|